Purpose: Cannabinoids modulate intestinal permeability through CB 1 . The endocannabinoidlike compounds oleoylethanolamine (OEA) and palmitoylethanolamine (PEA) play an important role in digestive regulation, and we hypothesised they would also modulate intestinal permeability.
Introduction
The human gastrointestinal tract forms the largest interface between the external environment and internal milieu (1) . Aside from its digestive functions, it also constitutes the most complex and most evolved element of immune defence. Intestinal epithelial cells, together with their mucous coatings, constitute a protective barrier across which paracellular permeation is selectively regulated by transmembrane protein contractility within the intercellular tight junctions (2, 3) . This prevents the loss of water and solutes from the gut, whilst simultaneously permitting the absorption of water and nutrients, but preventing the ingress of toxins, antigens and pathogens (4) (5) (6) . Impaired intestinal barrier function leading to hyperpermeability is associated with a wide variety of human diseases and conditions, for example acutely in shock and multiple organ-system dysfunction with splanchnic ischaemia (3), sepsis (2) , or more gradually, including inflammatory bowel disease (7) (8) (9) (10) , coeliac disease (11) , irritable bowel syndrome (12, 13 ) and a range of other conditions (14, 15) .
Family studies have demonstrated that increased intestinal permeability can precede the clinical presentation of inflammatory bowel disease (16) (17) (18) . The regulation of intestinal permeability is poorly understood, and improved understanding is required for the development of therapeutic interventions specifically targeted at restoring normal permeability (19) .
Cannabis sativa plant extracts have been used anecdotally over 5 millennia for the treatment of gastrointestinal disorders including nausea, vomiting, anorexia, intestinal inflammation and diarrhoea (20) . Endocannabinoids are intercellular lipid signalling molecules derived from arachidonic acid and synthesized on demand from cell membrane precursors. Examples were found to be expressed in the gut only 20 years ago (21), and subsequently endocannabinoids and their receptors were shown to be key regulators of a variety of gastrointestinal functions including emesis (22) , intestinal motility (23) and secretion (24) .
Endocannabinoids play significant roles in inflammation and apoptosis (25, 26) and specifically in intestinal inflammation (27) , opening up the possibility of new therapeutic options (28) .
Endocannabinoids exert their effects by activation of cannabinoid receptors (CB 1 and CB 2 ) (29) and other target sites of action such as transient receptor potential ion channels (TRPs) (30) , peroxisome proliferator-activated receptors (PPARs), (31) and orphan G-protein coupled receptors GPR119 (32) and GPR55 (33) . All of these target sites are expressed in the gastrointestinal tract. These receptors, together with endocannabinoid ligands and the enzymes responsible for their metabolism, are collectively referred to as the 'endocannabinoid system' (ECS). The ECS is involved in modulating gastrointestinal motility and intestinal inflammation, and is up-regulated in intestinal inflammation. Our group has previously reported that cannabinoids modulate intestinal permeability in vitro using Caco-2 intestinal cells (34, 35) , which has also been shown in vivo (36) . The plantderived cannabinoids, Δ 9 tetrahydrocannabinol (THC) and cannabidiol (CBD) reversed the increased permeability caused by EDTA or cytokines via CB 1 receptor activation (34, 35) .
By contrast, the endocannabinoids anandamide (AEA) and 2-arachidonoylglycerol (2-AG)
increased permeability of the Caco-2 monolayer via the CB 1 receptor (34, 35) , and inhibiting their synthesis improved the effects of inflammation on permeability, suggesting that the endogenous production of these compounds in response to inflammation plays a role in promoting permeability changes at the epithelium.
Oleoylethanolamine (OEA) is an endocannabinoid-like compound that does not bind to cannabinoid receptors (37) . OEA is produced on demand in enterocytes, and its production is stimulated by food intake (38) or reduced by food deprivation (39) . OEA is a PPARα agonist (40) , activates TRPV1 channels (41) , and the orphan G-protein-coupled receptors GPR55 and GPR119 (42) . OEA administration suppresses food intake, decreases body weight gain (43) and induces satiety via PPARα activation (44) . It also has a role in lipid metabolism regulation (45) , reducing cholesterol levels in mice via PPARα (40, 46) .
Palmitoylethanolamine (PEA) is another endocannabinoid-like compound found in high levels in the upper GI tract compared to other organs and tissues (39) . PEA reduces intestinal injury and inflammation in mice via PPARα (47, 48) . More recently, oral or intra-peritoneal administration of PEA was found to reduce inflammation and damage in dinitrobenzene sulfonic acid (DNBS)-induced colitis in mice, mediated by PPARα, CB 2 and GPR55 (49) and inhibition of the enzyme responsible for PEA degradation also reduces inflammation in two mouse models of colitis (50) .
In the present study, we hypothesised that OEA and PEA, which often have opposing physiological actions and different pharmacology to AEA and 2-AG, might also modulate intestinal permeability and play a role in intestinal inflammation. Specifically, we hypothesised that these compounds would have a beneficial effect on intestinal permeability based on their positive effects in vivo in simulated inflammation.
Materials and Methods

Cell culture
Caco-2 cells (European Collection of Cell Culture, Wiltshire, UK; passages 62-86) were cultured in T75 cell culture flask in Minimal Essential Medium Eagle supplemented with 10% fetal bovine serum, 1% penicillin/streptomycin and L-glutamine at 37°C in 5% CO2 and 95% air.
Effects of OEA and PEA on Caco-2 monolayer permeability
The cells were seeded at 20,000 cells on 6.4mm diameter, 0.4µm pore size polyethylene terephthalate inserts (BD Falcon Biosciences, UK) and grown for 14-18 days. Transepithelial electrical resistance (TEER) was measured using a voltohm meter (EVOM 2 ) (World Precision Instruments, Sarasota FL, USA) as an indicator of cellular permeability. Caco-2 cell monolayers with TEER value greater than 1000 Ω.cm 2 were used. Caco-2 cell monolayers were washed twice in HBSS (+ N-2-hydroxyethylpintestinal permeabilityerazine-N'-2-ethanesulfonic acid or HEPES and P/S) and baseline TEER measured. Increasing concentrations of OEA or PEA (1nM to 10µM) or vehicle (0.1% ethanol) were applied in pre-warmed MEME medium to the apical or basolateral compartment of inserts, and TEER was measured over the next 48h.
The following target sites of action were investigated (receptor antagonist and concentrations shown in brackets); CB 1 (AM251, 100nM (K i 7.49 nM)), CB 2 (AM630,
(IC 50 240 nM)), TRPV1 (Capsazepine, 1μM (K i 3.2 μM)) and proposed endothelial cannabinoid receptor antagonist (O-1918, 1μM ). In some experiments, OEA and PEA (3µM)
were applied with an inhibitor of their degradation by fatty acid amide hydrolase (FAAH), using URB597 (1µM), in absence and presence of capsazepine or GW6471.
To simulate inflammatory conditions, 10ng.ml -1 of Interferon-γ (IFNγ) was added basolaterally. After 8h, 10ng.ml -1 tumour necrosis factor-α (TNFα) was added for another 16
h. OEA and PEA were added to the apical or basolateral compartment at various time points, either at the same time as IFNγ (time 0h, to potentially block the development of inflammation), or after the induction of inflammation (at 24h, 48h or 72 h) to potentially limit the inflammatory increase in permeability). In some experiments, this was done in the presence of antagonists. For prolonged (chronic) inflammatory studies (see Figure 6 ), repeated applications of 3 ng.ml -1 of INFγ and TNFα were used.
Cell viability assays
To test the effects of OEA and PEA on cell viability in fully differentiated Caco-2 cells, Cells UK) were applied to membranes at room temperature for 1 h. Blots were exposed using Clarity™ Western ECL Substrate (BioRad, Hertfordshire, UK) and imaged with the BioRad ChemiDoc™ XRS system. These experiments were performed on four separate occasions.
To further elucidate the potential signalling proteins involved, Luminex® xMAP® technology was used to detect changes in phosphorylated CREB (pS133), ERK (pT185/pY187), NFκB (pS536), JNK (pT183/pY185), p38 (pT180/pY182), p70 S6K To detect changes in aquaporin expression at the cell membrane, the Mem-Per TM Plus
Membrane protein extraction kit was used to isolate the membrane protein fraction, and commercially available ELISAs were used to measure aquaporin 3 (LS-F13078, LifeSpan
Biosciences Inc) and aquaporin 4 (LS-F13079, LifeSpan Biosciences Inc.)
Potassium channel activation
To test the ability of OEA and PEA to modulate potassium channels in Caco-2 cells, the to channel activity, which was compared to the effects of a high potassium solution ( Figure   1G ).
Measurement of endocannabinoid levels
A quantitative LC-MS/MS method was used for analysis of OEA and PEA in cell samples, based on a previously reported procedure (51) . For these experiments, Caco-2 cells were grown in T75 flasks and subjected to inflammatory conditions (10 ng.ml (Shimadzu, Columbia, MD, USA) using an ACE 3 C8, 100 x 2.1 mm, 3 µm particle size column (Advanced Chromatography Technologies Ltd., Aberdeen, UK). Quantification was performed by measuring specific OEA and PEA precursor and product ions together with a calibrated internal standard method.
Chemicals and reagents
All chemicals and reagents used in these experiments were purchased from Sigma-Aldrich (Poole, UK) unless otherwise stated. OEA and PEA and the receptor antagonists AM251, AM630, GW9662, GW6471, capsazepine and O-1918 were purchased from Tocris (R&D Systems, UK). OEA and PEA were dissolved in ethanol to 10mM with further dilutions made in MEME. All receptors antagonists were dissolved in dimethyl sulfoxide (DMSO) to 10mM
with further dilutions in MEME. Interferon-γ (IFNγ, 100μg) and Tumour Necrosis Factor-α (TNFα, 50μg) purchased from Invitrogen (Paisley, UK) and dilutions were made in fetal bovine serum (FBS).
Statistical analysis
Values are expressed as mean ± SEM. Time-course data was compared by 2 way, repeated measures (repeated by time factor) analysis of variance (ANOVA) using GraphPad Prism 6
(GraphPad Software, Inc., La Jolla, CA, USA). Statistical significance between manipulations and vehicle controls were determined by Dunnett's post-hoc test. P<0.05 was considered statistically significant.
Results
Permeability studies
Our initial experiments sought to explore whether the N-acylethanolamines were able to modulate the ionic conductance of the paracellular pathway, as a proxy for tight junction integrity. When applied to the apical membrane compartment, OEA increased Caco-2 cell monolayer transepithelial electrical resistance (TEER) (i.e. decreased permeability) in a concentration-dependent manner significantly different from control at 1, 3 and 10µM
( Figure 1A ). When applied to the basolateral membrane, OEA decreased TEER (i.e.
increased permeability) in a concentration-dependent manner at 1, 3 and 10µM ( Figure 1C ).
The Log EC 50 of OEA at the apical membrane was -5.43 and at the basolateral membrane was -5.92 (see Supplemental Figure 1A ).
PEA caused a large increase in TEER when applied to the apical membrane at 1, 3
and 10µM ( Figure 1B To ensure that these changes in permeability were not related to changes in cell number, we carried out cell viability assays. Neither OEA nor PEA affected Caco-2 cell viability in fully confluent (see Supplemental Figure 2A ) or proliferating (see Supplemental 
Intracellular signalling
Since the action of the contractile cytoskeleton enables the cellular changes required to adjust permeability in response to its environment, we investigated the signalling events known to be important for cytoskeletal modifications, namely focal adhesion kinase (FAK) and the p42/44 MAP kinases (52) . OEA induced a transient increase in both FAK and Erk1/2 ( Figure   2 , left panel, top and third blot down), peaking at 5 min and returning to basal levels by 30 min (Figure 3B,C) . PEA induced phosphorylation of Erk1/2 to significant higher levels than OEA (Fig 3A, right panel, third blot down), but FAK activation by PEA continued to increase up to 1 hour post application (Fig 3B,C, right panel, top blot) .
We carried out further experiments using Luminex technology and commercially available panels for multiple pathways and the SRC pathway. As seen with western blotting ( Figure 1A ), OEA significantly increased phosphorylated ERK1/2 and also p70s6K, CREB and NF Κ B, and significantly decreased phosphorylated p38 and JNK ( Figure 3D ). PEA significantly increased phosphorylated ERK1/2, p70s6K, and CREB, and significantly decreased phosphorylated p38 ( Figure 3E ). In this panel, significant differences between OEA and PEA were observed in the ERK1/2 and Akt response (see Supplemental Figure   4D ,F). In the Src family panel of signalling proteins, OEA and PEA significantly reduced phosphoylated Src, Yes, Lck, Lyn, Fgr, and Blk (significance is not shown in Figure 3F and G for clarity, please refer to Supplemental Figure 5 ). OEA also significantly reduced phosphoylated Fyn and Hck. This was more pronounced at 10 min for OEA ( Figure 3F ) and at 2 min for PEA ( Figure 3G ).
Receptor mechanism of action
The ability of a submaximal concentration of OEA (3 µM, apical application) to increase TEER was inhibited by capsazepine (a TRPV1 antagonist) only ( Figure 4A ). The ability of OEA (3 µM, basolateral) to decrease TEER was inhibited by the TRPV1 antagonist capsazepine and the PPARα receptor antagonist GW6471 ( Figure 4C ). The effect of PEA at the apical membrane was inhibited by the PPARα antagonist GW6471 ( Figure 4B ). The effect of PEA at the basolateral membrane was inhibited by a PPARα antagonist ( Figure 4D ).
OEA and PEA are degraded by fatty acid amid hydrolase (FAAH). When OEA or PEA were applied in combination with the FAAH inhibitor URB597, their effects were amplified. OEA (3 µM, apically) caused further increases in TEER when co-applied with a FAAH inhibitor (URB597, Figure 5A ) to the apical membrane, and this was inhibited by TRPV1 antagonism ( Figure 5A ). OEA (3 µM) also caused further decrease in resistance when co-applied with URB597 to the basolateral membrane, via TRPV1 and PPARα ( Figure   5C ). PEA (3 µM) caused further increases in resistance when co-applied with URB597 (at either the apical or basolateral membrane) and this was inhibited by the PPARα antagonist GW6471 ( Figure 5B,D) .
Effects of OEA and PEA on cytokine-induced hyperpermeability
When applied to the apical membrane concurrently with cytokines, OEA (3µM) prevented the fall in TEER ( Figure 6A ). Apically, OEA also recovered the increased permeability when applied 24h after cytokines ( Figure 5B ). By contrast, application of OEA to the basolateral membrane (at either time 0 or 24h) caused further decreases in TEER than caused by cytokines alone, indicating further increased permeability ( Figure 6A ,B).
PEA (3µM) prevented the drop in TEER caused by cytokines when applied at the same time to the basolateral membrane, evident at early as 8 h into the cytokine exposure (IFNγ exposure only, Figure 6A ). This effect of PEA at the basolateral membrane was still observed when PEA was applied 24h after exposure to cytokines ( Figure 6B ). However, PEA has no effect on cytokine-increased permeability when applied to the apical membrane at either time-point ( Figure 6A ,B).
To establish whether OEA and PEA are produced endogenously in cells in response to simulated inflammatory conditions, cellular and secreted levels of these compounds were measured by LC-MS/MS after the inflammation protocol used to assess permeability changes. Cellular levels of OEA (P<0.001, Figure 6C ) and PEA (P<0.01, Figure 5E ) were significantly increased by the inflammatory protocol. Significantly raised levels of OEA (P<0.0001, Figure 6D ) and PEA (P<0.001, Figure 6F ) were also detectable in the medium in response to simulated inflammation.
Mechanisms of action of OEA and PEA on cytokine-induced hyperpermeability
When applied to the apical membrane concurrently with cytokines, as before ( Figure 6 ), OEA (3µM) prevented the fall in TEER, and this effect was inhibited by the TRPV1 antagonist capsazepine ( Figure 7A ). Apically, OEA also recovered the increased permeability when applied 24h after cytokines, also inhibited by capsazepine ( Figure 7C ). As before, application of OEA to the basolateral membrane caused further decrease in TEER (when added at time 0 or 24 h), which inhibited by the PPARα antagonist GW6471 but not capsazepine ( Figure 7A ,C).
As before, PEA (at the basolateral membrane) prevented the drop in TEER caused by cytokines when applied with at the same time or 24 h later, which was inhibited by GW6471
( Figure 7B,D) .
The effects of OEA and PEA on prolonged cytokine exposure
Lastly, we examined whether OEA and PEA can alter the permeability response to prolonged cytokine exposure. 48 h after application of cytokines, apical application of OEA was able to restore permeability to baseline ( Figure 8A ). However, after 72 h inflammation, this ability of OEA was lost ( Figure 8C ). At the basolateral membrane, PEA was able to restore permeability to baseline when applied 48 h after cytokine exposure ( Figure 8B ) and even after 72 h after cytokine exposure ( Figure 8D ), and this effect of PEA was inhibited by the PPARα antagonist GW6471 ( Figure 8D ).
Discussion
This study has shown the effects of the endocannabinoid-like compounds OEA and PEA on the function and permeability of intestinal epithelial cells in control conditions and in inflammation. Both compounds were able to reverse the hyperpermeability associated with inflammatory conditions through different mechanisms; OEA through TRPV1 on the apical membrane, and PEA at the basolateral membrane through PPARα. Increased cellular and secreted OEA and PEA levels were observed in response to inflammation, suggesting their local release plays a role in intestinal permeability. Inhibition of the degradation of these compounds augmented their responses, indicating their effects are via the compounds themselves and not by their metabolites. It also suggests that the beneficial effects of these compounds could be augmented by co-administration of inhibitors of their degradation.
OEA
OEA production in the gut is stimulated by food intake (38) or reduced by food deprivation (39) . OEA suppresses food intake, induces satiety and decreases body weight gain (43) Contractile filamentous actin networks regulate cellular shape change, which can be spatially and temporally modulated during physiological processes such as cell adhesion,
where cytoskeletal mechanics facilitate cell spreading and stiffening in response to environmental cues. F-actin structures such as lamella and stress fibres can facilitate adhesion, whereas cortical F-actin influences shape. FAK is a non-receptor protein kinase that can modulate barrier function (52) , and our data confirms that OEA transiently activates FAK. However, the F-actin changes that ensue are twofold. Apically, the cortical arrangement indicates shape change, whereas basally, the filamentous structure was reduced.
Reduced adhesion at the base of the cells could explain why OEA has a differential effect on TEER depending on where it is acting. It is unclear how the change in apical morphology connects to a change in cell-cell junctional complexes such that the interactions are tighter, but certainly reduced cellular adhesion to the extracellular matrix (or glass slide in this instance) could account for the OEA effect on permeability when applied basally. It is important to note that cells remain attached to each other with no gaps, implying that the changes in permeability are not related to pore formation or destruction of the epithelial monolayer (also indicated by the lack of effect of OEA on cell viability).
There are many molecular markers that are associated with barrier integrity and membrane permeability. Apical junctional complex structure can be dynamic and the precise location of some of the component parts can influence the final outcome. The contribution and mechanisms of aquaporins in regulation of membrane permeability in the gut is unclear.
In our study the reduction in AQP4 membrane protein expression by OEA was unlikely to affect water transport since knockdown of AQP4 does not impact on the colonic osmotic water permeability coefficient (53, 54) , but could be related to other functions, such as the intestinal inflammatory response (55) . With regard to AQP3, apical expression in the ileum is reduced in early IBD (56), which may be to limit excessive water loss or alleviate oxidative stress. However, Zhang and colleagues (57) did show that intestinal barrier integrity was impaired by the knockdown of AQP3 by enhancement of paracellular permeability. OEA lead to a modest reduction in expression of AQP3 in our study that would be unlikely to impact on TEER through water transport. The role of these aquaporins in glycerol and lipid metabolism is beyond the scope of this study, although it is tempting to speculate that the accepted contribution of OEA in fat sensing and transport of dietary lipids (58) could be mediated through aquaporin expression.
We also showed that OEA activated potassium channels in Caco-2 cells, which has been previously observed for OEA in arteries (59, 60) . Potassium channel activation in the intestine is associated with many aspects of colonic epithelial function including regulating electrogenic transport, regulating cell volume and cellular migration (61, 62) , suggesting OEA modulates epithelial cell functions in the intestine at many levels, which requires further investigation.
Regulation of the intercellular junctional interactions that maintain barrier function is highly complex. However, FAK activity through phosphorylation has been well correlated with TEER and that Src-dependency may be crucial to this function, particularly in Caco-2 cells (52). In our study, OEA transiently increased the autophosphorylation of FAK, but interestingly reduced Src phosphorylation in the same timeframe. Reduced phosphorylation of Src and JNK have been shown to attenuate stretch-induced reorganisation of the actin cytoskeleton (63) and increased Src is associated with tight junction disruption in the intestinal epithelium (64) . The increase in p70S6K and CREB phosphorylation is likely to relate to downstream gene transcription and protein translation, which is similar to PEA.
However, the increase in NF-κB activity, which is unique to OEA in this system, requires further investigation. NF-κB has pleiotropic roles in cell survival and the immune response.
The precise role of NF-kB in TEER in this context is unclear, but may explain the basolateral reduction in TEER, reminiscent of TNFα-induced barrier disruption (65).
In our model of inflammation, IFNγ and TNFα applied to the basolateral membrane of confluent Caco-2 cells increased permeability, similar to that previously reported by our group (35) . We found that application of OEA apically, concurrently with the cytokines, or even after 24 or 48 hours later, reversed the increased permeability via TRPV1. This is the first study to investigate the effects of OEA on intestinal permeability in vitro, but OEA has been found to decrease blood brain barrier permeability in ischemia in vivo and in vitro, similarly by PPARα activation (66) . Pharmacological activation of TRPV1 may contribute to colonic inflammation (30) , thus the anti-inflammatory actions of OEA through TRPV1, may be brought about by desensitisation of the TRPV1 receptor. We also showed that inflammation significantly increased OEA levels in Caco-2 cells, suggesting these observations of the pharmacological effects of OEA have a physiological relevance. Others have similarly shown that OEA is upregulated in response to inflammation (67) or by feeding (68) , and this may be as a result of increased OEA synthesis or reduced degradation.
To summarise the effects of OEA, at the apical membrane OEA decreases permeability and inhibits increased permeability when applied before or after the induction of increased permeability associated with inflammation via TRPV1 activation, and inflammation increases cellular levels of OEA. By contrast, at the basolateral membrane, OEA causes increased permeability through both TRPV1 and PPARα. Activation of FAK, inactivation of Src, changes in F-actin, activation of K + channels and downregulation of aquaporins may underlie these cellular responses to OEA.
PEA
PEA is currently available as a nutraceutical food for medical purposes under the brand names Normast ® , Pelvilen ® and PeaPure ® , and has been studied in humans, mostly within trials on pain management, and is well tolerated (69) . Several preclinical animal studies have
shown that in vivo treatment with PEA reduces intestinal injury and inflammation via PPARα (47, 48) , and also CB 2 and GPR55 (49) . In support of this, we showed that PEA decreases Caco-2 cell permeability when applied to either the apical or basolateral membrane in a timeand a concentration-dependent fashion, also via activation of the PPARα receptor.
Furthermore, basolateral application of PEA, as might occur with systemic administration, also reversed the hyperpermeability associated with inflammation via PPARα. Unlike with OEA, there was no negative (i.e. increased permeability) response to PEA application at either membrane. In inflammation, this beneficial effect of PEA was observed when PEA was added before the insult, or even after 24, 48 and 72 hours post induction of inflammation.
This ability of PEA to prevent increased permeability at the intestine barrier, via PPARα, is likely to underpin some of the beneficial effects seen in vivo. The increase in cellular PEA levels in response to our inflammatory protocol is in keeping with the proposed protective effects of endogenously produced PEA in the gut (70) (71) (72) .
Like OEA, PEA also induced FAK activity, but the timing was more extended and the F-actin lamella structure seen with PEA was pronounced. These differences imply different cellular outcomes. The effect of PEA on the filament formation appears more typical in that 
